Bioventus (NASDAQ:BVS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Bioventus (NASDAQ:BVS) had its target price upped by research analysts at Canaccord Genuity Group from $15.00 to $19.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 33.24% from the stock’s previous close.

Several other research firms have also issued reports on BVS. Barrington Research set a $18.00 price objective on Bioventus in a research note on Thursday, August 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 target price on shares of Bioventus in a research report on Monday. Craig Hallum reissued a “buy” rating and set a $18.00 target price on shares of Bioventus in a research report on Thursday, August 6th. Finally, Weiss Ratings upgraded Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.80.

Bioventus Stock Performance

Bioventus stock opened at $14.26 on Monday. The company’s 50-day moving average price is $11.36 and its 200-day moving average price is $9.91. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83. The company has a market cap of $1.20 billion, a PE ratio of 18.52, a price-to-earnings-growth ratio of 1.82 and a beta of 0.63. Bioventus has a twelve month low of $6.26 and a twelve month high of $15.89.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.22 EPS for the quarter, meeting analysts’ consensus estimates of $0.22. The firm had revenue of $153.21 million during the quarter. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities research analysts forecast that Bioventus will post 0.79 EPS for the current fiscal year.

Institutional Trading of Bioventus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BVS. Caitong International Asset Management Co. Ltd boosted its position in shares of Bioventus by 17,156.2% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after buying an additional 5,490 shares during the period. Diversified Trust Co bought a new position in shares of Bioventus during the first quarter valued at approximately $100,000. Prelude Capital Management LLC purchased a new stake in shares of Bioventus in the third quarter worth approximately $74,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Bioventus in the third quarter worth approximately $78,000. Finally, Brooklyn Investment Group bought a new stake in shares of Bioventus during the 4th quarter worth approximately $91,000. 62.94% of the stock is owned by hedge funds and other institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.